Cost effectiveness of peginterferon α-2b plus ribavirin versus interferon α-2b plus ribavirin for initial treatment of chronic hepatitis C

U. Siebert; G. Sroczynski; S. Rossol; J. Wasem; U. Ravens-Sieberer; B. M. Kurth; M. P. Manns; J. G. McHutchison; J. B. Wong; W. Greiner; J. M G vonderSchulenburg; M. Bullinger; P. Aidelsburger; F. Hessel; F. Buchner; M. Corzillius; F. H. Anderson; S. Arora; B. Bacon; L. Balart; K. G. Benner; M. A. Bigard; H. C. Bodenheimer; M. Bourliere; C. Brechot; H. Brunner; S. Caldwell; W. Carey; R. L. Carithers; G. L. Davis; J. Dienstag; J. Donovan; R. Esteban-Mur; M. Buti; G. T. Everson; S. Feinman; S. Flamm; P. R. Galle; R. Gish; N. Gitlin; T. Goeser; S. Gordon; H. Greten; S. Hadzyiannis; I. Hokeberg; I. Jacobson; P. Kwo; D. R. LaBrecque; W. M. Lee; S. Lindgren; K. L. Lindsay; M. P. Manns; P. Marcellin; P. Marotta; T. McGarrity; J. G. McHutchison; R. Moreno; T. R. Morgan; R. Perrillo; M. Poliquin; T. Poynard; J. Rakela; R. Reindollar; J. L. Rodriguez-Agullo; R. Rouzier-Panis; V. Rustgi; J. M. Sanchez-Tapias; E. R. Schiff; D. Schuppan; M. Sherman; M. L. Shiffman; M. Silva; C. Smith; H. Tanno; C. Trepo; W. Vogel; T. Wright; S. Zeuzem

doi:10.1136/gut.52.3.425

Cost effectiveness of peginterferon α-2b plus ribavirin versus interferon α-2b plus ribavirin for initial treatment of chronic hepatitis C

U. Siebert, G. Sroczynski, S. Rossol, J. Wasem, U. Ravens-Sieberer, B. M. Kurth, M. P. Manns, J. G. McHutchison, J. B. Wong, W. Greiner, J. M G vonderSchulenburg, M. Bullinger, P. Aidelsburger, F. Hessel, F. Buchner, M. Corzillius, F. H. Anderson, S. Arora, B. Bacon, L. BalartK. G. Benner, M. A. Bigard, H. C. Bodenheimer, M. Bourliere, C. Brechot, H. Brunner, S. Caldwell, W. Carey, R. L. Carithers, G. L. Davis, J. Dienstag, J. Donovan, R. Esteban-Mur, M. Buti, G. T. Everson, S. Feinman, S. Flamm, P. R. Galle, R. Gish, N. Gitlin, T. Goeser, S. Gordon, H. Greten, S. Hadzyiannis, I. Hokeberg, I. Jacobson, P. Kwo, D. R. LaBrecque, W. M. Lee, S. Lindgren, K. L. Lindsay, M. P. Manns, P. Marcellin, P. Marotta, T. McGarrity, J. G. McHutchison, R. Moreno, T. R. Morgan, R. Perrillo, M. Poliquin, T. Poynard, J. Rakela, R. Reindollar, J. L. Rodriguez-Agullo, R. Rouzier-Panis, V. Rustgi, J. M. Sanchez-Tapias, E. R. Schiff, D. Schuppan, M. Sherman, M. L. Shiffman, M. Silva, C. Smith, H. Tanno, C. Trepo, W. Vogel, T. Wright, S. Zeuzem

Research output: Contribution to journal › Article › peer-review

200 Scopus citations

Abstract

Background: Peginterferon α-2b plus ribavirin therapy in previously untreated patients with chronic hepatitis C yields the highest sustained virological response rates of any treatment strategy but is expensive. Aims: To estimate the cost effectiveness of treatment with peginterferon α-2b plus ribavirin compared with interferon α-2b plus ribavirin for initial treatment of patients with chronic hepatitis C. Methods: Individual patient level data from a randomised clinical trial with peginterferon plus ribavirin were applied to a previously published and validated Markov model to project lifelong clinical outcomes. Quality of life and economic estimates were based on German patient data. We used a societal perspective and applied a 3% annual discount rate. Results: Compared with no antiviral therapy, peginterferon plus fixed or weight based dosing of ribavirin increased life expectancy by 4.2 and 4.7 years, respectively. Compared with standard interferon α-2b plus ribavirin, peginterferon plus fixed or weight based dosing of ribavirin increased life expectancy by 0.5 and by 1.0 years with incremental cost effectiveness ratios of €11 800 and €6600 per quality adjusted life year (QALY), respectively. Subgroup analyses by genotype, viral load, sex, and histology showed that peginterferon plus weight based ribavirin remained cost effective compared with other well accepted medical treatments. Conclusions: Peginterferon α-2b plus ribavirin should reduce the incidence of liver complications, prolong life, improve quality of life, and be cost effective for the initial treatment of chronic hepatitis C.

Original language	English (US)
Pages (from-to)	425-432
Number of pages	8
Journal	Gut
Volume	52
Issue number	3
DOIs	https://doi.org/10.1136/gut.52.3.425
State	Published - Mar 1 2003

ASJC Scopus subject areas

Gastroenterology

Access to Document

10.1136/gut.52.3.425

Cite this

Siebert, U., Sroczynski, G., Rossol, S., Wasem, J., Ravens-Sieberer, U., Kurth, B. M., Manns, M. P., McHutchison, J. G., Wong, J. B., Greiner, W., vonderSchulenburg, J. M. G., Bullinger, M., Aidelsburger, P., Hessel, F., Buchner, F., Corzillius, M., Anderson, F. H., Arora, S., Bacon, B., ... Zeuzem, S. (2003). Cost effectiveness of peginterferon α-2b plus ribavirin versus interferon α-2b plus ribavirin for initial treatment of chronic hepatitis C. Gut, 52(3), 425-432. https://doi.org/10.1136/gut.52.3.425

Siebert, U, Sroczynski, G, Rossol, S, Wasem, J, Ravens-Sieberer, U, Kurth, BM, Manns, MP, McHutchison, JG, Wong, JB, Greiner, W, vonderSchulenburg, JMG, Bullinger, M, Aidelsburger, P, Hessel, F, Buchner, F, Corzillius, M, Anderson, FH, Arora, S, Bacon, B, Balart, L, Benner, KG, Bigard, MA, Bodenheimer, HC, Bourliere, M, Brechot, C, Brunner, H, Caldwell, S, Carey, W, Carithers, RL, Davis, GL, Dienstag, J, Donovan, J, Esteban-Mur, R, Buti, M, Everson, GT, Feinman, S, Flamm, S, Galle, PR, Gish, R, Gitlin, N, Goeser, T, Gordon, S, Greten, H, Hadzyiannis, S, Hokeberg, I, Jacobson, I, Kwo, P, LaBrecque, DR, Lee, WM, Lindgren, S, Lindsay, KL, Manns, MP, Marcellin, P, Marotta, P, McGarrity, T, McHutchison, JG, Moreno, R, Morgan, TR, Perrillo, R, Poliquin, M, Poynard, T, Rakela, J, Reindollar, R, Rodriguez-Agullo, JL, Rouzier-Panis, R, Rustgi, V, Sanchez-Tapias, JM, Schiff, ER, Schuppan, D, Sherman, M, Shiffman, ML, Silva, M, Smith, C, Tanno, H, Trepo, C, Vogel, W, Wright, T & Zeuzem, S 2003, 'Cost effectiveness of peginterferon α-2b plus ribavirin versus interferon α-2b plus ribavirin for initial treatment of chronic hepatitis C', Gut, vol. 52, no. 3, pp. 425-432. https://doi.org/10.1136/gut.52.3.425

@article{553d6cd566f74bbda992789c8d34de38,

title = "Cost effectiveness of peginterferon α-2b plus ribavirin versus interferon α-2b plus ribavirin for initial treatment of chronic hepatitis C",

abstract = "Background: Peginterferon α-2b plus ribavirin therapy in previously untreated patients with chronic hepatitis C yields the highest sustained virological response rates of any treatment strategy but is expensive. Aims: To estimate the cost effectiveness of treatment with peginterferon α-2b plus ribavirin compared with interferon α-2b plus ribavirin for initial treatment of patients with chronic hepatitis C. Methods: Individual patient level data from a randomised clinical trial with peginterferon plus ribavirin were applied to a previously published and validated Markov model to project lifelong clinical outcomes. Quality of life and economic estimates were based on German patient data. We used a societal perspective and applied a 3% annual discount rate. Results: Compared with no antiviral therapy, peginterferon plus fixed or weight based dosing of ribavirin increased life expectancy by 4.2 and 4.7 years, respectively. Compared with standard interferon α-2b plus ribavirin, peginterferon plus fixed or weight based dosing of ribavirin increased life expectancy by 0.5 and by 1.0 years with incremental cost effectiveness ratios of €11 800 and €6600 per quality adjusted life year (QALY), respectively. Subgroup analyses by genotype, viral load, sex, and histology showed that peginterferon plus weight based ribavirin remained cost effective compared with other well accepted medical treatments. Conclusions: Peginterferon α-2b plus ribavirin should reduce the incidence of liver complications, prolong life, improve quality of life, and be cost effective for the initial treatment of chronic hepatitis C.",

author = "U. Siebert and G. Sroczynski and S. Rossol and J. Wasem and U. Ravens-Sieberer and Kurth, {B. M.} and Manns, {M. P.} and McHutchison, {J. G.} and Wong, {J. B.} and W. Greiner and vonderSchulenburg, {J. M G} and M. Bullinger and P. Aidelsburger and F. Hessel and F. Buchner and M. Corzillius and Anderson, {F. H.} and S. Arora and B. Bacon and L. Balart and Benner, {K. G.} and Bigard, {M. A.} and Bodenheimer, {H. C.} and M. Bourliere and C. Brechot and H. Brunner and S. Caldwell and W. Carey and Carithers, {R. L.} and Davis, {G. L.} and J. Dienstag and J. Donovan and R. Esteban-Mur and M. Buti and Everson, {G. T.} and S. Feinman and S. Flamm and Galle, {P. R.} and R. Gish and N. Gitlin and T. Goeser and S. Gordon and H. Greten and S. Hadzyiannis and I. Hokeberg and I. Jacobson and P. Kwo and LaBrecque, {D. R.} and Lee, {W. M.} and S. Lindgren and Lindsay, {K. L.} and Manns, {M. P.} and P. Marcellin and P. Marotta and T. McGarrity and McHutchison, {J. G.} and R. Moreno and Morgan, {T. R.} and R. Perrillo and M. Poliquin and T. Poynard and J. Rakela and R. Reindollar and Rodriguez-Agullo, {J. L.} and R. Rouzier-Panis and V. Rustgi and Sanchez-Tapias, {J. M.} and Schiff, {E. R.} and D. Schuppan and M. Sherman and Shiffman, {M. L.} and M. Silva and C. Smith and H. Tanno and C. Trepo and W. Vogel and T. Wright and S. Zeuzem",

year = "2003",

month = mar,

day = "1",

doi = "10.1136/gut.52.3.425",

language = "English (US)",

volume = "52",

pages = "425--432",

journal = "Gut",

issn = "0017-5749",

publisher = "BMJ Publishing Group",

number = "3",

}

TY - JOUR

T1 - Cost effectiveness of peginterferon α-2b plus ribavirin versus interferon α-2b plus ribavirin for initial treatment of chronic hepatitis C

AU - Siebert, U.

AU - Sroczynski, G.

AU - Rossol, S.

AU - Wasem, J.

AU - Ravens-Sieberer, U.

AU - Kurth, B. M.

AU - Manns, M. P.

AU - McHutchison, J. G.

AU - Wong, J. B.

AU - Greiner, W.

AU - vonderSchulenburg, J. M G

AU - Bullinger, M.

AU - Aidelsburger, P.

AU - Hessel, F.

AU - Buchner, F.

AU - Corzillius, M.

AU - Anderson, F. H.

AU - Arora, S.

AU - Bacon, B.

AU - Balart, L.

AU - Benner, K. G.

AU - Bigard, M. A.

AU - Bodenheimer, H. C.

AU - Bourliere, M.

AU - Brechot, C.

AU - Brunner, H.

AU - Caldwell, S.

AU - Carey, W.

AU - Carithers, R. L.

AU - Davis, G. L.

AU - Dienstag, J.

AU - Donovan, J.

AU - Esteban-Mur, R.

AU - Buti, M.

AU - Everson, G. T.

AU - Feinman, S.

AU - Flamm, S.

AU - Galle, P. R.

AU - Gish, R.

AU - Gitlin, N.

AU - Goeser, T.

AU - Gordon, S.

AU - Greten, H.

AU - Hadzyiannis, S.

AU - Hokeberg, I.

AU - Jacobson, I.

AU - Kwo, P.

AU - LaBrecque, D. R.

AU - Lee, W. M.

AU - Lindgren, S.

AU - Lindsay, K. L.

AU - Manns, M. P.

AU - Marcellin, P.

AU - Marotta, P.

AU - McGarrity, T.

AU - McHutchison, J. G.

AU - Moreno, R.

AU - Morgan, T. R.

AU - Perrillo, R.

AU - Poliquin, M.

AU - Poynard, T.

AU - Rakela, J.

AU - Reindollar, R.

AU - Rodriguez-Agullo, J. L.

AU - Rouzier-Panis, R.

AU - Rustgi, V.

AU - Sanchez-Tapias, J. M.

AU - Schiff, E. R.

AU - Schuppan, D.

AU - Sherman, M.

AU - Shiffman, M. L.

AU - Silva, M.

AU - Smith, C.

AU - Tanno, H.

AU - Trepo, C.

AU - Vogel, W.

AU - Wright, T.

AU - Zeuzem, S.

PY - 2003/3/1

Y1 - 2003/3/1

N2 - Background: Peginterferon α-2b plus ribavirin therapy in previously untreated patients with chronic hepatitis C yields the highest sustained virological response rates of any treatment strategy but is expensive. Aims: To estimate the cost effectiveness of treatment with peginterferon α-2b plus ribavirin compared with interferon α-2b plus ribavirin for initial treatment of patients with chronic hepatitis C. Methods: Individual patient level data from a randomised clinical trial with peginterferon plus ribavirin were applied to a previously published and validated Markov model to project lifelong clinical outcomes. Quality of life and economic estimates were based on German patient data. We used a societal perspective and applied a 3% annual discount rate. Results: Compared with no antiviral therapy, peginterferon plus fixed or weight based dosing of ribavirin increased life expectancy by 4.2 and 4.7 years, respectively. Compared with standard interferon α-2b plus ribavirin, peginterferon plus fixed or weight based dosing of ribavirin increased life expectancy by 0.5 and by 1.0 years with incremental cost effectiveness ratios of €11 800 and €6600 per quality adjusted life year (QALY), respectively. Subgroup analyses by genotype, viral load, sex, and histology showed that peginterferon plus weight based ribavirin remained cost effective compared with other well accepted medical treatments. Conclusions: Peginterferon α-2b plus ribavirin should reduce the incidence of liver complications, prolong life, improve quality of life, and be cost effective for the initial treatment of chronic hepatitis C.

AB - Background: Peginterferon α-2b plus ribavirin therapy in previously untreated patients with chronic hepatitis C yields the highest sustained virological response rates of any treatment strategy but is expensive. Aims: To estimate the cost effectiveness of treatment with peginterferon α-2b plus ribavirin compared with interferon α-2b plus ribavirin for initial treatment of patients with chronic hepatitis C. Methods: Individual patient level data from a randomised clinical trial with peginterferon plus ribavirin were applied to a previously published and validated Markov model to project lifelong clinical outcomes. Quality of life and economic estimates were based on German patient data. We used a societal perspective and applied a 3% annual discount rate. Results: Compared with no antiviral therapy, peginterferon plus fixed or weight based dosing of ribavirin increased life expectancy by 4.2 and 4.7 years, respectively. Compared with standard interferon α-2b plus ribavirin, peginterferon plus fixed or weight based dosing of ribavirin increased life expectancy by 0.5 and by 1.0 years with incremental cost effectiveness ratios of €11 800 and €6600 per quality adjusted life year (QALY), respectively. Subgroup analyses by genotype, viral load, sex, and histology showed that peginterferon plus weight based ribavirin remained cost effective compared with other well accepted medical treatments. Conclusions: Peginterferon α-2b plus ribavirin should reduce the incidence of liver complications, prolong life, improve quality of life, and be cost effective for the initial treatment of chronic hepatitis C.

UR - http://www.scopus.com/inward/record.url?scp=0037372609&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037372609&partnerID=8YFLogxK

U2 - 10.1136/gut.52.3.425

DO - 10.1136/gut.52.3.425

M3 - Article

C2 - 12584228

AN - SCOPUS:0037372609

SN - 0017-5749

VL - 52

SP - 425

EP - 432

JO - Gut

JF - Gut

IS - 3

ER -

Cost effectiveness of peginterferon α-2b plus ribavirin versus interferon α-2b plus ribavirin for initial treatment of chronic hepatitis C

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this